Cytokinetics’ (aficamten) met both primary endpoints in the Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy (nHCM). Already approved for obstructive HCM, the drug could soon double its market.
The FDA has approved Cytokinetics' MYQORZO (aficamten), a groundbreaking treatment for adults with symptomatic obstructive hypertrophic cardiomyopathy to improve heart function and reduce symptoms.
Cytokinetics' experimental drug Aficamten demonstrates superior improvements in exercise capacity and cardiac function compared to standard care for obstructive hypertrophic cardiomyopathy, with a favorable safety profile across multiple studies.
